Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma

Ann Oncol. 2007 Nov;18(11):1906-7. doi: 10.1093/annonc/mdm489.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Atrial Fibrillation / chemically induced
  • Atrial Fibrillation / physiopathology
  • Benzenesulfonates / adverse effects*
  • Benzenesulfonates / therapeutic use
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / pathology
  • Carcinoma, Renal Cell / secondary*
  • Cardiovascular Diseases / chemically induced*
  • Cardiovascular Diseases / physiopathology
  • Chest Pain / chemically induced
  • Chest Pain / physiopathology
  • Drug Interactions
  • Follow-Up Studies
  • Humans
  • Indoles / adverse effects*
  • Indoles / therapeutic use
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / pathology
  • Middle Aged
  • Myocardial Ischemia / chemically induced
  • Myocardial Ischemia / physiopathology
  • Neoplasm Invasiveness / pathology
  • Neoplasm Staging
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / adverse effects*
  • Pyridines / therapeutic use
  • Pyrroles / adverse effects*
  • Pyrroles / therapeutic use
  • Risk Assessment
  • Sampling Studies
  • Severity of Illness Index
  • Sorafenib
  • Sunitinib

Substances

  • Benzenesulfonates
  • Indoles
  • Phenylurea Compounds
  • Pyridines
  • Pyrroles
  • Niacinamide
  • Sorafenib
  • Sunitinib